# Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

> **NCT00621686** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 54 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00621686
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-10
- **Final completion:** 2014-02-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621686, "Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00621686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*